The newly launched platform, Alcami Biologics, will advance commercialization of biological products, as the market for biopharmaceuticals and outsourced biological drug development services continues to expand.
A spokesperson for Alcami told us, “Current market growth projections mirror the dramatic increases in demand we’ve seen firsthand for specialized biopharmaceutical testing and manufacturing services. Biologics may be the future of growth for contract development and manufacturing organizations (CDMOs) like ourselves.”
“Biological products are some of the most effective therapeutics in the world and represent an increasing segment of our overall portfolio. The new Alcami Biologics platform better positions our organization to meet our clients’ highly complex development and manufacturing needs and deliver their breakthrough treatment programs to patients faster,” they continued.
Alcami Biologics service offerings will be supported by three of the company’s facilities.
The company’s Wilmington, North Carolina, site will provide analytical development and testing services for protein and peptide biologics, as well as cell line characterization and analytical testing of cell and gene therapies. Its Durham, North Carolina, plant provides bioassay development and its Charleston, South Carolina, site provides current good manufacturing practice (cGMP) for clinical and commercial parenteral manufacturing and lyophilization services.
The company’s 20 liquid chromatography (HPLC) systems, four triple quadrupole mass spectrometers (TQMS), and two quadruple time-of-flight (QToF) mass spectrometers will be available to clients.